Anidulafungin versus fluconazole for invasive candidiasis.

Reboli, Annette C; Rotstein, Coleman; Pappas, Peter G; Chapman, Stanley W; Kett, Daniel H; Kumar, Deepali; Betts, Robert; Wible, Michele; Goldstein, Beth P; Schranz, Jennifer; Krause, David S; Walsh, Thomas J

Reboli, Annette C; Rotstein, Coleman; Pappas, Peter G; Chapman, Stanley W; Kett, Daniel H; Kumar, Deepali; Betts, Robert; Wible, Michele; Goldstein, Beth P; Schranz, Jennifer; Krause, David S; Walsh, Thomas J.

Affiliation

Reboli AC; University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and Cooper University Hospital, Camden, NJ 08103, USA. reboli-annette@cooperhealth.edu

N Engl J Med ; 356(24): 2472-82, 2007 Jun 14.

Article in En | MEDLINE | ID: mdl-17568028

Subject(s)

Antifungal Agents/therapeutic use; Candidiasis/drug therapy; Fluconazole/therapeutic use; Fungemia/drug therapy; Peptides, Cyclic/therapeutic use; Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents/adverse effects; Candida/isolation & purification; Candidiasis/mortality; Double-Blind Method; Echinocandins; Female; Fluconazole/adverse effects; Fungemia/mortality; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Peptides, Cyclic/adverse effects; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Peptides, Cyclic / Candidiasis / Fluconazole / Fungemia / Antifungal Agents Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: N Engl J Med Year: 2007 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links